Collectively, these results highlighted HPK1 in NK cells as a candidate target for treating metastatic cancer and its cooperative therapeutic combination with anti‐PD‐1 and anti‐CTLA‐4 therapy. Here, PDCD1 is linked to metastatic malignant neoplasm.